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Abstract
Introduction: Obsessive compulsive disorder (OCD) is a common disabling condition, which 
greater than 40% of patients do not respond to the available treatment options. Imbalances in 
the cortical-striatal-thalamic-cortical circuits have proven to be useful psychosurgical treat-
ment targets making this circuit disorder an optimal target for intervention with TMS. 
Methods: PubMed and clinicaltrials.gov were reviewed for sham-controlled therapeutic 
rTMS studies for OCD. 
Results: Eighteen relevant studies are presented in a narrative fashion along with rel-
evant methodological details, and distinctions.
Conclusions: High and low frequency stimulation to lateral prefrontal cortices does not 
appear to have consistent efficacy in the small studies done to date. Several small stud-
ies with non-blinded operators suggest that low frequency high intensity rTMS to the 
supplementary motor area with a figure-8 coil reduces OCD symptoms. A fully blinded 
multicenter center study is warranted to confirm this finding. A promising pilot study 
and a subsequent multicenter study of high frequency high intensity deep rTMS with the 
HAC/H7 coil to the bilateral prefrontal orbitofrontal and anterior cingulate cortices were 
completed with positive results. Many areas of uncertainty remain, such as the optimal 
state of the circuitry during stimulation and identifying a priori biomarkers for respond-
ers and non-responders to specific protocols.
Keywords: rTMS, dTMS, TMS, OCD, ACC, SMA, OFC, obsessive compulsive disorder
1. Introduction
The DSM 5 criteria for obsessive compulsive disorder (OCD) are specific. Patients can have 
either obsessions, compulsions or both. Obsessions are defined as unwanted thoughts, images 
or urges. Compulsions are repetitive behaviors or mental acts that are done in response to an 
obsession or a rigid rule with the aim of reducing anxiety. However, the extent of the compulsion 
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is either unrealistic or excessive. Obsessions and/or compulsions must take up at least 1 h a day, 
and though it may relieve their anxiety, it should not be pleasurable to the patient. In addition to 
the time component, the obsessions-compulsions should cause significant impairment in social 
or occupational functioning. The OCD symptoms should not be due to a substance or another 
disorder. Specifiers for OCD in the DSM 5 include the degree of insight (good, fair, poor, absent, 
delusional beliefs) and tic related [1].
2. Epidemiology
The 12-month prevalence of OCD in the United States is 1.2%, with similar prevalence inter-
nationally (1.1–1.8%). Females are affected at a slightly higher rate than males in adulthood; 
although males are more commonly affected in childhood. The mean age at onset of OCD is 
19.5 years and 25% of cases start by 14 years old. Onset after 35 years is unusual but does occur. 
Males have an earlier age of onset than females; nearly 25% of males have onset before the age of 
10. The onset of symptoms is typically gradual; however, acute onset has also been reported [1].
If OCD is untreated, the course is usually chronic, often with waxing and waning symptoms. 
Some have an episodic course and a minority has a deteriorating course. Without treatment, 
remission rates in adults are low (i.e. 20%). Onset in childhood or adolescence can lead to a 
lifetime of OCD. However, 40% of individuals with childhood or adolescent onset of OCD 
may experience remission by early adulthood. The course of OCD is often complicated by the 
co-occurrence of other disorders. Compulsions are more easily diagnosed in children than 
obsessions, because compulsions are observable. However, most children have both [1].
2.1. Prognostic factors
Greater internalizing symptoms, higher negative emotionality, and behavioral inhibition in 
childhood are possible temperamental risk factors. Physical and sexual abuse in childhood and 
other stressful or traumatic events have been associated with an increased risk for developing 
OCD. Some children develop the sudden onset of OCD symptoms after streptococcal infection, 
and subsequently it is not distinguishable from OCD for the duration of their lives. In others, it 
has more motor symptoms and is amenable to antibiotic treatment if it is treated immediately.
2.2. Comorbidities
Most OCD patients (76%) have a lifetime history of another anxiety disorder. Specifically, 
63% have lifetime history of mood disorder, 41% have major depressive disorder, 23–32% has 
comorbid obsessive-compulsive personality disorder, 29% have lifetime history of tic disor-
der, and 12% have schizophrenia. Additional common diagnoses include bipolar, anorexia, 
bulimia and Tourette’s [1].
2.3. Heritability
OCD may be the most heritable psychiatric condition, with a monozygotic twin concordance 
rate of 0.52 and a dizygotic concordance rate of 0.21, with overall heritability for OCD estimated 
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to be 48% [2]. The overall recurrence rate (another first degree family member getting OCD) is 
about 50%, which is higher with Tourette’s and tics as well as childhood onset. It is lower with 
pure OCD of adult onset [3].
3. Current available treatment options for OCD
At the present time, exposure and response prevention should probably be the first line treat-
ment for non-comorbid OCD. Pharmacologic interventions with significant evidence for 
efficacy, specifically with 8–12 weeks of medication results with greater than 30% improve-
ment for 40–60% of OCD patients include several selective serotonin reuptake inhibitors: 
Fluoxetine, Paroxetine, Fluvoxamine and Sertraline in the USA; Citalopram and Escitalopram 
in Europe; and the tricyclic, Clomipramine.
Neurosurgery has shown promising outcomes where 58–67% of patients showed marked 
improvement in numerous studies even for patients who have refractory OCD (failed three 
medications and had 6 months of exposure and response prevention). The primary ablation 
anatomical targets are the fiber tracts that connect the cortex to thalamic nuclei, the anterior 
limb of the internal capsule and the cingulate gyrus. Nevertheless, neurosurgical procedures 
also yield reports of transient and persistent adverse effects [4].
Deep brain stimulation (DBS) has several advantages over ablation. Surgeons using DBS can 
potentially achieve a clinical effect without producing an irreversible lesion. The efficacy of 
ablative lesions appears to be similar to DBS.
4. Why do we need TMS for OCD?
Over 1% of the population has no improvement from current approved treatments. Even the 1% 
that benefits from current approved treatments is actually still quite affected by their OCD. We 
use improvement criteria in OCD trials rather than response and remission, similar to schizophre-
nia. Schizophrenia affects 1% of the population, and there are over 20 antipsychotics available in 
most countries. OCD affects 2.3% of the population, and there are only 5 approved medications.
5. OCD as a circuit disorder
Several inclusive models have been suggested to explain the neurobiology of OCD. One is 
an executive dysfunction model, where there are deficits in impulse control and inhibition of 
behaviors. Another is a modulatory control model, where the main dysfunction is in regulat-
ing socially appropriate behaviors. A recent model proposes OCD as an uncertainty disor-
der where there is an imbalance between input and input suppression [5]. Regardless of the 
model, there is abnormal activity in a region of the cortical-striatal-thalamic-cortical circuits. 
These are multiple parallel interconnected loops between cortical and subcortical areas whose 
role is to screen out which actions are selected and which are considered maladaptive and 
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ignored. These regions include the dorsolateral prefrontal cortex (DLPFC), orbitofrontal cor-
tex (OFC), medial prefrontal cortex (mPFC), cingulate cortex, caudate nucleus, striatum and 
thalamus. An abnormality in the functioning of this pathway results in impulsivity, compul-
sivity, obsessivity, uncertainty, deficits in attentional allocation, sensory-motor gating, modu-
lation of motor activity and more [6, 7].
The greatest evidence for OCD as a circuit disorder comes from the success of circuit inter-
ventions at various locations along the pathway. Specifically, circuit interventions have 
demonstrated efficacy at the striatum, globus pallidus interna, substantia nigra, thalamus, 
subthalamic nucleus, anterior cingulate cortex (ACC), OFC and anterior capsulotomy [5].
6. TMS systems for OCD
6.1. Coil types
Transcranial magnetic stimulation (TMS) uses magnetic pulses to induce electrical current in 
the underlying neuronal tissue. There are a variety of different TMS coils on the market, and 
they differ primarily with the orientation and flexibility of the wire windings in the coil. Several 
types of coils have been used in sham-controlled OCD studies. The first is a rigid circular coil. 
These are typically large and very non-focal as the induced current is identical in intensity 
anywhere under the wire. The orientation of the current in relation to the neurons is important. 
The coil can be reoriented 180° to switch the direction of the current under one side of the coil, 
but the other side of the coil will still have an effect. The second is a figure-8 or butterfly shaped 
coil. This is a rigid coil, usually in a 180° plane, which induces the strongest current beneath the 
center of the two circular coils. However, the field decays relatively rapidly. The manufacturer 
for most of the research figure-8 systems is Magstim, but Magventure (formerly Medtronic) 
makes a double-blind figure-8 system as well. Approximately 20 companies make active fig-
ure-8 coils. An option not yet used is a bent or double cone coil, which is also a rigid coil, but it 
is larger and bent at a 120° fixed angle. It is capable of reaching a greater depth than a figure-8 
coil. To date, it has never been used in an OCD clinical trial, but it is made by many companies 
similarly to the figure-8 coil. The newest coil on the market is the H7 or HAC-coil. It has flexible 
windings that run along the skull and sum at depth, and these windings are tightened to the 
head. It can reach 3 cm beneath the cortex at high frequency and high intensity; additionally, 
the magnetic field decays slowly. The H-coil has gaps between the central groups, which make 
the field different from the fixed denser distribution of the bent or double cone coil. The H7/
HAC coil had the largest and only multicenter sham-controlled OCD study to date.
6.2. Cooling systems
When TMS is done repetitively (rTMS), especially at high frequencies for long periods of time, 
the coils will heat up. To prevent this from occurring, the coils are cooled using one of three 
methods; fan cooled with room temperature air (Magstim), liquid cooled (Magventure or Mag 
and More), or fan cooled with a forced cooled air system (Brainsway). The figure-8 coil and bent 
coil are available liquid cooled or fan cooled. The H-coil uses a forced air conditioning system.
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6.3. Blinding system
Clinical trials with TMS ideally should include blinding for the patient, rater and operator. 
However, in order for the operator of the TMS device to be blinded a unique research TMS 
system is required. Because of this many TMS studies do not have a blinded TMS operator 
and the sham arm has the operator rotate the coil 90° against the scalp delivering cutaneous 
stimulation with the identical sound. Magventure manufactures a double-blind coil, which 
is in one device; then, the computer tells the operator which side of the coil to use for the 
patient. Magstim has separate active and sham coils. When conducting a clinical trial, one can 
use coil A or coil B, as well as a third coil to determine the motor threshold. Both the Magstim 
and Magventure, require a cutaneous nerve stimulator to induce a superficial sensation dur-
ing the sham train. Some single-blind studies do not even create a cutaneous sensation at all. 
Brainsway has the most practical approach, since the H-coil is in a helmet both the active and 
sham coil is in the same helmet. The subject is assigned a card that interacts with the stimula-
tor and coil through an interface module. The motor threshold is determined with an opera-
tor card; then the coil is advanced to the treatment position, and the subject card is inserted, 
which selects whether the sham or active coil is activated. The sham coil is made of conical 
windings that do not penetrate the cortex; so, the identical sound and a superficial sensation 
are felt, but no neuronal stimulation is induced.
7. Detailed review of sham-controlled trials using TMS for treatment 
refractory OCD
In the following paragraphs, the sham-controlled or multi-arm therapeutic studies of TMS for 
OCD are described in detail. For an overview, please see Table 1.
In 2001, Pino Alonso published a sham-controlled TMS study whereby 18 OCD patients were 
administered active (N = 10) or sham (N = 8) rTMS for 18 sessions (3 times a week for 6 weeks). 
Active and sham treatments were administered using low frequency rTMS (1 Hz, 1200 pulses) 
to the right prefrontal cortex (PFC) using a 70 mm circular coil. The active group was admin-
istered 110% of the left hand resting motor threshold (MT) and the sham group was adminis-
tered 20%MT. Raters and patients were blinded, and operators were unaware of the expected 
effects of the prescribed intensity. Neither the sham nor active treatment groups had signifi-
cant reduction in their OCD symptoms following 18 sessions of low frequency rTMS over the 
right PFC with a circular coil for 6 weeks [8].
Sachdev et al. randomly designated 12 treatment-resistant OCD subjects to right (n = 6) or 
left (n = 6) prefrontal rTMS treatment groups. Both groups were administered a figure-8 coil 
for 10 treatments over 2 weeks at 10 Hz for 1500 pulses at 110% MT. An independent rater 
evaluated progress once a weekly during treatment then at the 1 month follow up. In both 
groups, there was a significant improvement after 2 weeks and at the 1 month follow up 
in the obsessions, compulsions, and total scores on the Yale-Brown Obsessive Compulsive 
Scale (Y-BOCS). There was not a significant difference between left and right-sided high 
frequency rTMS [9].
TMS for OCD
http://dx.doi.org/10.5772/intechopen.73594
93
Study Device Location Protocol Sample 
size
Blinding Outcome
Patient Operator Rater
Alonso [8] Magstim circular Right PFC 1 Hz, 1200P, 110%MT 10 + + No significant reduction in OCD
Sham: 20%MT 8
Sachdev [9] Magstim figure 8 Right PFC 10 Hz, 1500P, 110%MT 6 - (ignorant to 
significance of 
laterality)
— + No significant difference between 
right and left high frequency. Both left 
and right groups had significant OCD 
improvement
Left PFC 10 Hz, 1500P, 110%MT 6
Prasko [10] Left DLPFC 1 Hz, 110%MT 15 Active did not have any greater benefit 
than sham
Sham 15
Sachdev [11] Magstim figure 8 Left DLPFC 10 Hz, 1500P, 110%MT 10 + — + No significant difference between active 
and sham after 10 sessions. There was a 
significant difference after 20 treatmentsSham 8
Ruffini [12] Magstim figure 8 Left OFC 1 Hz, 600P, 80%MT 16 + — There was a significant difference 
between active and sham, which lasted 
10 weeks after TMS endedSham: (coil 
perpendicular to scalp)
7
Mantovani 
[13]
Magstim figure 8 Pre-SMA 1 Hz, 1200P, 100%MT 9 + — + The active TMS group had 25% 
reduction in YBOCS compared to 12% 
reduction in shamSham: coil with a mu 
shield
9
Mansur [14] Medtronic figure 8 Right 
DLPFC
10 Hz, 2000P, 110%MT 13 + — + There was no difference in any of the 
outcome measures between active and 
shamSham 14
Gomes [15] Neuro-MS figure 8 Pre-SMA 1 Hz, 1200P, 100%MT 12 + — + Significant reduction in YBOCS 
compared to sham
Sham 10
Ma [16] αEEG guided 
rTMS (Cadwell 
9 cm circular coil)
Midfrontal 
region
648–872P, 80%MT 25 + + + Significant reduction of YBOCS 
compared to sham
Sham 21
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Study Device Location Protocol Sample 
size
Blinding Outcome
Patient Operator Rater
Haghihagi 
[17]
Magstim figure 8 Left DLPFC Crossover study: 
20 Hz, 100%MT then 
sham
21 + — + YBOCS improved after active rTMS
Crossover study: sham 
then 20 Hz, 100%MT
21
Elbeh [18] Magstim figure 8 Right 
DLPFC
1 Hz, 2000P, 100%MT 15 + — + Significant improvement compared to 
sham
10 Hz, 2000P, 100%MT 15 No significant improvement compared 
to sham
Sham 15
Hawken [19] Medtronic figure 8 SMA 1 Hz, 1200P, 110%MT 10 + — + Active TMS had significant reduction in 
YBOCS compared to sham
Sham: (coil rotated 
away from head)
12
Seo [20] Tamas/remed 
figure 8
Right 
DLPFC
1 Hz, 1200P, 100%MT 14 + — + Significant reduction in YBOCS compared 
to sham
Sham 13
Pallanti [21] Magstim 70-mm 
figure 8
SMA 1 Hz, 1200P, 100%MT 25 — — — Effective in 2/3 patients.
TAU: Antipsychotics 25 Effective in ¼ patients.
Pelissolo 
[22]
Magstim 70-mm 
figure 8
Pre-SMA 1 Hz, 1500P, 100%MT 20 + — + No significant difference.
Sham: coil with mu 
shield
19
Shayganfard 
[23]
Magstim figure 8 Left DLPFC Crossover study: 
20 Hz, 750P, 100%MT 
then Sham
10 + — + YBOCS improved after active rTMS
Crossover study: sham 
then 20 Hz, 750P, 
100%MT
10 TMS for OCD
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Study Device Location Protocol Sample 
size
Blinding Outcome
Patient Operator Rater
Carmi [25] Brainsway dTMS 
H7
dmPFC/
ACC
20 Hz 16 + + + Improvement compared to sham
Sham: 20 Hz 7
1 Hz 8 No difference between 1 Hz & 1 Hz sham
Sham: 1 Hz 7
Brainsway 
Ltd. [26]
Brainsway dTMS 
H7
dmPFC/
ACC
20 Hz, 2000P, 100%MT 47 + + + Improvement compared to sham
Sham 47
Table 1. Individual characteristics of sham-controlled therapeutic TMS studies for OCD.
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In 2006, Prasko conducted a sham-controlled study of 30 OCD patients, half were assigned to 
sham and half to active low frequency rTMS. Ten treatments over 2 weeks were administered 
of low frequency rTMS to the left DLPFC (1 Hz, 110% MT, total pulses not available to this 
author). The active group did not have any greater benefit than the sham group [10].
In 2007, Perminder Sachdev published the results of a 2-week sham-controlled study for OCD 
in which the patients and raters were blinded; but the operators were not. Ten subjects were 
randomized to active and eight to sham. High- frequency (10 Hz, 5 second train, 25 second 
inter-train interval, 30 trains, 1500 total pulses, at 110% of resting right hand MT) rTMS was 
administered to the left DLPFC in 10 sessions over 2 weeks with a figure-8 coil. Patients were 
offered to extend treatment up to 20 sessions. No significant difference was found between 
the treatment groups in YBOCS or Maudsley Obsessive-Compulsive Inventory scores after 10 
sessions. There was a significant difference in YBOCS after 20 treatments; however, it was not 
significant after controlling for depression [11].
In 2009, Chiara Ruffini published the results of a single-blind left OFC rTMS study of 23 
patients with medication resistant OCD. Using a figure-8 coil, he administered low frequency, 
subthreshold rTMS (1 Hz, 80% MT, 600 pulses) to the left OFC (fp1 on EEG system) with the 
coil parallel to the scalp for the 16 subjects randomized to active. The coil was positioned 
perpendicular to the scalp for the seven subjects randomized to sham. There was a significant 
difference between active and sham low frequency stimulation of the left OFC which lasted 
until 10 weeks after rTMS ended. Only one of the seven patients had a placebo response, and 
of the 16 active patients, four had a greater than 35% reduction in the YBOCS from baseline. 
It is not clear (to this writer) why no one replicated the results of this study on a larger scale, 
longer treatment duration in double blinded format [12].
In 2010, Antonio Mantovani published the results of a 4 week double blinded study of 1HZ 
rTMS to the bilateral pre supplementary motor area (SMA) at 100%MT of the thumb for 1200 
pulses in 18 medication and cognitive behavioral therapy (CBT) resistant OCD patients with 
a figure-8 coil. The operators were not blinded, and they used a sham coil with a mu shield; 
but the patients and raters were blinded. On average at 4 weeks, the active TMS group had 
a 25% reduction in YBOCS compared to a 12% reduction in the sham group. Patients who 
subsequently continued an additional 4 weeks of open label treatment generally had an addi-
tional three-point decrease in their YBOCS. The results were promising but the active group 
only had nine completers [13].
In 2011, Carlos Gustavo Mansur published the results of a sham-controlled study of high fre-
quency, high intensity right DLPFC rTMS for OCD using a figure-8 coil. In this study, operators 
were not blinded but the patients and raters were blinded. Thirteen patients received active and 
14 patients received sham. rTMS was administered at 110% of resting left hand MT, 10HZ, 5 sec-
ond trains, 25 second intervals, 40 trains, 2000 total pulses for 30 treatments over 6 weeks. There 
was no difference in any of the outcome measures between the active and sham groups [14].
In 2012, Pablo Vinicius Oliveira Gomes randomized 22 patients with moderate OCD into 
active (n = 12) or sham (n = 10) groups. The study was blinded to the subjects and raters; 
however, the TMS operators were not blinded. Patients received 10 rTMS treatment sessions 
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over 2 weeks utilizing a figure-8 coil with low frequency (1 Hz), 1200 pulses at 100% MT over 
the bilateral pre SMA. They were assessed 3 months after completing TMS. At the 2 week and 
14 week assessments, the active group had a significant reduction of 35% in YBOCS scores 
compared to the sham group who had a 6.2% reduction [15].
In 2014, Xiaoyan Ma published a randomized single-blind sham-controlled study that enrolled 46 
subjects with moderate to severe OCD. The study’s goal was to determine the treatment effect of 
using the patient’s individualized alpha electroencephalogram (αEEG)-guided rTMS (αTMS) in 
OCD patients. Treatment was administered with a 9 cm circular coil placed over the midfrontal 
region. Twenty-five OCD patients received αTMS at 80% resting MT of the hand, 4 seconds stim-
ulation, 56 seconds interval, 20 minutes stimulation daily, total pulses varied by patient’s alpha 
between 648 and 872 pulses per day for 10 treatment sessions over 2 weeks. Twenty-one patients 
received sham stimulation using an unplugged coil with acoustic effects from another coil at 
a distance. At the end of treatment and the 1 week follow up, the obsession component of the 
YBOCS was significantly reduced in the active treatment group compared to the sham group [16].
In 2015, Mohammad Haghihagi published the results of a single blinded crossover trial of 21 
OCD patients. Stimulation was administered at 20 Hz, 100% resting right hand MT, 1.5 sec-
ond train, 25 trains, totaling 750 pulses, 5 days a week for 2 weeks. Sham stimulation was 
done with the coil angled away from the skull. After 2 weeks, patients switched conditions for 
an additional 2 weeks. In both groups, the patient’s YBOCS improved after the active rTMS 
condition and not during the sham condition [17].
In 2016, Khaled Elbeh randomized 45 patients into a trial to evaluate the effects of different 
rTMS frequencies over the right DLPFC at 100% resting left hand MT using a figure-8 coil. 
Fifteen patients received low frequency (1 Hz), 15 high frequency (10 Hz), and 15 received 
sham. The operators were not blinded. All groups were administered 10 sessions over 2 weeks 
of 2000 pulses each at 100% MT; then, patients were followed for 3 months post rTMS. The 
low frequency group but not the high frequency group’s YBOCS was significantly different 
than sham. The effects did not last 3 months [18].
In 2016, Emily Hawken published a two-site randomized, placebo-controlled clinical trial for 
patients with refractory OCD using low frequency rTMS to the bilateral SMA. Ten patients 
received active and 12 patients were in the placebo group, where the operators rotated the coil 
away from the skull. rTMS was administered at 1HZ, 110% of resting hand MT, 1200 pulses 
for 25 sessions over 6 weeks with a figure-8 coil. Active TMS recipients obtained significant 
reductions in their YBOCS compared to sham. Benefits were maintained for 6 weeks after 
treatment [19]. This is the third small sham-controlled study showing the benefits low fre-
quency figure-8 rTMS over the SMA.
In 2016, Ho Jun Seo published a 3-week single-blind study of low frequency rTMS to the right 
DLPFC with a figure-8 coil (Tamas, Remed). Fourteen patients received active and 13 patients 
received sham rTMS, 1 Hz, 1200 pulses, 100%MT of the left hand 5 days a week for 3 weeks. 
The active group had a significant YBOCS reduction compared to sham [20].
In 2016, Stefano Pallanti published the results of an open-label trial with 50 patients with SSRI 
refractory OCD. Patients were randomized into either the TAU (treatment as usual) (n = 25) 
or rTMS (n = 25) groups. The TAU group was treated with antipsychotic drugs. In the rTMS 
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group, patients were administered 15 sessions of rTMS over 3 weeks with a 70 mm Figure 8 
coil at 1 Hz, 1200 pulses, 100%MT over the SMA. One quarter of the refractory OCD patients 
who were treated with antipsychotics responded compared to the subjects treated with rTMS 
where two thirds were responders [21].
In 2016, Antoine Pelissolo published the results of a randomized double-blind study of 40 
SSRI treatment-resistant OCD patients. Subjects were randomized into active (n = 16) or sham 
(n = 15) groups. The patients and raters were blinded; however, the operators were not. Both 
groups were administered rTMS with the 70 mm figure-8 coil at 1 Hz for 1500 pulses, 100%MT 
to the pre-SMA for 4 weeks. The sham coil utilized a mu-metal shield over the figure-8 coil. 
The active group did not have a significant reduction in YBOCS compared to sham [22].
In 2017, Mehran Shayganfard published the results of a single-blind crossover study of high 
frequency rTMS to the left DLPFC of 10 OCD patients using a figure-8 coil. Stimulation was 
administered at 20 Hz, 100% resting right hand MT, 1.5 second train, 25 trains, totaling 750 
pulses, 5 days a week for 2 weeks. Sham stimulation was done with the coil angled away 
from the skull. After 2 weeks, patients switched conditions for an additional 2 weeks. In both 
groups, the patient’s YBOCS improved after the active rTMS condition and not after the sham 
condition [23, 24]. This was the second single blinded study this group did with the same 
crossover after 2 weeks [17, 23]. Methodologically, they should do a double-blind non-cross-
over study, and at a significantly later date offer the sham patients active treatment.
Between 2012 and 2014, a feasibility study used an H-coil designed to target the medial 
prefrontal cortices and anterior cingulate cortices (ACC) bilaterally (HAC or H7 coil) in 41 
treatment-resistant obsessive-compulsive-disorder (OCD) patients with moderate to severe 
symptoms. Treatments were administered after the patient’s individual symptoms were 
provoked, and improvements were measured using the YBOCS. Initially the study had four 
arms, a high frequency arm of 20 Hz, a sham 20 Hz arm, a low frequency arm of 1 Hz and 
a sham 1 Hz arm. Because the interim analysis showed no difference between the sham and 
1 Hz arms, the study was continued with just high frequency and sham. At the end of the 
study, the response rate in the 20 Hz arm was much greater than in the sham group and the 
improvements were still present a month after treatments ended [25, 26].
Subsequently, from 2014 to 2017 94 patients with moderate to severe treatment-resistant OCD 
were randomized in a multicenter double-blind study to either 20 Hz active or sham dTMS, at 
100% resting MT of the foot, 2 second trains, 20 second inter train intervals, 2000 total pulses per 
day. Treatments were administered daily for 29 days over 6 weeks after the patient’s individual 
symptoms were provoked, with a follow up at week 10. Although the study has been com-
pleted with a public announcement of positive results, the details have not been published yet.
8. Conclusion-key results
OCD is uniquely suited for intervention with TMS. However, rTMS interventions in OCD that 
focus on the lateral prefrontal cortices in both high and low frequency are not consistently 
efficacious. Most of the small sham-controlled studies treating the SMA, left DLPFC, and right 
DLPFC with low frequency as well as high frequency showed benefit. This is consistent with 
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the results of a recently published meta-analysis. The meta-analysis noted the right DLPFC 
had a greater therapeutic effect than other treatment locations [27]. The next step should be a 
fully blinded (including the operators) sham-controlled multicenter study of low frequency 
rTMS to the SMA (the pre-SMA is the anterior portion of the SMA, and it is a midline region 
so it is always treated bilaterally even with a figure-8 coil). Two high frequency, high intensity 
studies using the HAC/H7 deep rTMS coil showed efficacy for OCD including a multisite 
study for FDA clearance. We await the detailed presentation of those results.
Further directions for the field include optimizing stimulation parameters for greater efficacy. 
What state should the circuitry be in during the stimulation? Does the treatment have durability 
or is maintenance necessary? If children and adolescents are treated early will it change the tra-
jectory of their illness? Does the same protocol work for OCD related disorders such as hoard-
ing, trichotillomania and body dysmorphic disorder? Does this work for OCD without insight 
or with delusions? Does it help with tics? What happens to the neural circuitry of the OCD 
patients responding to TMS? Can non-responders benefit from an individualized protocol? Can 
we predict responders from non-responders before we go through an entire treatment course?
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